Sutura Therapeutics Completes Investment Round
Sutura Therapeutics completes seed investment round (total £7.8M, $9.4) to develop its peptide-based PeptiGo technology platform.
MACCLESFIELD, UK (RNS REACH) - Sutura Therapeutics Ltd, a private biopharmaceutical company developing peptide-based biomolecular medicinal products, today announces that it has received the final tranche of a £7.8M ($9.4M) seed funding round. The funding has already enabled the Company to establish its research operations at Alderley Park, Macclesfield, UK and will now further support the development of its proprietary peptide-based PeptiGo platform.
The funding round was led by Elevat3 Capital, the venture capital arm of serial entrepreneur and investor Christian Angermayer and his family office, Apeiron Investment Group. Elevat3 has joined Sutura's Board of Directors.
Incorporated in 2020, Sutura's patented PeptiGo platform generates synthetic biomolecules with a rigid peptide domain, which confers both enhanced delivery efficiency and tissue-specificity. With applications for both new and existing nucleic acid payloads, PeptiGos promise to rejuvenate less effective nucleic treatments and create new opportunities to access previously undruggable targets. The Company's lead product SUT-001 is an exon-skipping antisense oligonucleotide-based PeptiGo, which is in pre-clinical development for the treatment of Duchenne Muscular Dystrophy. SUT-001 has shown enhanced performance in pre-clinical testing, compared to existing treatments.
James Noble, Chairman, said "Sutura will enable the development of much needed new medicines to be developed for a wide range of diseases, including those that currently have no effective treatment. We are delighted with the continuous support of Elevat3 and the syndicate of experienced investors. This is a testament to the growth potential of the Company's technology and the strength of the team."
Thomas Hanke, Founding Partner at Elevat3 Capital added: "We were impressed by the Company's technology platform and look forward to helping Sutura realize the full potential of its ground-breaking approach."
About Sutura Therapeutics Ltd
Sutura Therapeutics is a biopharmaceutical company with a focus on developing next-generation biomolecular medicines, harnessing the potential of its proprietary PeptiGo technology platform. Sutura's platform technology represents a breakthrough in synthetic biomolecule design, overcoming the limitations of conventional biomolecules to tackle previously undruggable diseases. For more information, please visit sutura.com.
For further information please contact: Dr Edwin Wagena, CEO (email: edwin.wagena@sutura.com, phone: +44 (0) 1625 315016).
Sutura Therapeutics Limited is a company incorporated in England and Wales under company number 12385038.
Registered Office: Alderley Park, Congleton Road, Nether Alderley, Cheshire, SK10 4TG, United Kingdom
www.sutura.com